Louisiana BIO Board of Directors

 
Unknown-1.jpeg

Aaron miscenich

Aaron Miscenich has been the President & CEO of the New Orleans BioInnovation Center since 2004. With an emphasis on entrepreneurship in the life sciences, the BioInnovation Center is a $48 million LEED Gold business incubator, focused primarily on the local commercialization of university technologies. The BioInnovation Center works with research institutions throughout Louisiana in moving a full range of technologies to market.

Miscenich also manages New Orleans BioFund, a $2.4 million evergreen capital source for the regional life science industry. Miscenich oversees the fund’s activity in equity investments, alternative finance/mezzanine lending, and senior debt transactions for start-ups and emerging companies.

From 2011 to 2015 Miscenich was selected to serve as interim Executive Director of the Louisiana Cancer Research Center (LCRC), a New Orleans-based research collaborative between LSU Health Science Center, Tulane University, Xavier University, and the Ochsner Health System.

Miscenich is currently the Chairperson of LouisianaBIO, the state affiliation the Biotechnology Industry Organization (BIO) and serves on the Board of Directors of the Association of University Research Parks (AURP).

Unknown-2.jpeg

Joseph F. Lovett

Mr. Lovett is a Managing Director of Louisiana Funds (LF I & II), two early stage venture capital funds with $40 million under management based in Louisiana with offices in New Orleans and Baton Rouge. LF’s focus is on forming early stage companies primarily based on research at the major Louisiana research universities (LSU, Tulane and Louisiana Tech University) in the areas of biotechnology, life sciences, pharmaceuticals, medical devices, agri-technology, engineering, software, security and internet technologies.

To date LF I has started or invested in 13 companies primarily based upon research licensed from the major research universities in Louisiana with 11 licenses (8 from LSU, 1 from Tulane and 2 from Louisiana Tech). In addition to the investment from Louisiana Fund I, an additional $150,000,000 has been raised from 16 venture capital and mezzanine investors for the 13 companies in the LF I portfolio.  Louisiana Fund II has invested in 7 early stage companies in Florida, Louisiana, Texas and Colorado.

Mr. Lovett has spent his entire 47 year career in the life sciences industry starting with CR Bard, Mallinckrodt and Damon Biotech in increasingly responsible positions in sales, marketing and general management.

Dale+Pfost.jpg

Dale R. Pfost

Dale Pfost is a Partner of the London-based Advent Life Sciences, one of the leading venture capital funds in Europe. Dale has 25 years of experience as a life science entrepreneur and senior executive. He is currently also serving as the acting CEO of MicroBiome Therapeutics and on the board of Aura BioSciences, an ophthalmic cancer company.

Dale has been the CEO of five successful biotechnology companies, three of which became publically traded, with valuations of over $1 Billion. He was the founding CEO of Acuity Pharmaceuticals which had the first-ever clinical trial with an siRNA drug and undertook a reverse merger to form OPKO Health (NYSE: OPK). He was the founding CEO of Oxford GlycoSciences and Orchid BioSciences, both of which had IPOs in 1998 and 2000 respectively. His first company, started while he was in grad school, was acquired by SmithKline Beckman and produced the Biomek, a leading laboratory automation system.

Dale has led 22 financings raising over $300 million, has led the M&A of nine companies and served on 16 boards of directors of public, private and non-profit companies. He has been with Advent Life Sciences for eight years. He has PhD in Physics from Brown University and a BS in Physics from UC Santa Barbara. He works from his two home offices, one in Los Altos, California and the other in New Orleans.

 
TG8_5055-2.jpg
Headshot.jpg
G_Davenport-color_headshot.jpg

Isabella sledge MD

Isabella Sledge MD, MPH – is a Founder and the VP of Research and Development at Tides Medical, a biotechnology company focused on regenerative medicine. Dr. Sledge is an internist and health outcomes researcher who has focused her career on evidence development for emerging healthcare technologies.

Dr. Sledge received her medical degree from University of Maryland School of Medicine and holds a Masters in Public Health from the Harvard School of Public Health.

Bruce greenstein

Bruce has spent the last 25 years in healthcare – split between the public sector and private sectors. He has led large agencies in state governments and offices across the U.S. Department of Health & Human Services.

In the private sector, Bruce has been an executive at one of the world’s largest corporations, one of healthcare’s hottest startups, and today he is at one of the nation’s largest home care companies. Bruce has also spent time in venture capital and private equity, and is on the board of a publicly traded health care company.

Gregory J. Davenport

Gregory J. Davenport, Ph.D., is currently President of Full Spectrum Omega, Inc., a Life Sciences Corporation developing phytocannabinoids to address unmet medical conditions and Principal & CEO of Davenport & Companies, LLC, a broad based professional management firm that provides value-added business solutions to various clients.

Known as a results oriented executive, Dr. Davenport has over 25 years of experience in building organizations and managing programs. Prior to joining Full Spectrum Omega, Inc., Dr. Davenport was a Vice President for a DC firm specializing in non-dilutive funding where he secured Federal contracts and in kind services for clients including a $21 million contact for a Virginia-based antibiotic company.

Throughout his career, Dr. Davenport has held various C-­‐level executive positions with biotech and life science companies including Tunnell Consulting (an employee-­‐owned company providing technical, organizational and operational consulting to Federal and Life Science clients), Dor Biopharma, Inc. (publicly traded biotech company), and Dynport Vaccine Company (previous subsidiary of CSC)) were he secured more than $350 M in non-­‐dilutive funding.

Dr. Davenport earned a Bachelor of Science degree from Dillard University in New Orleans, Louisiana, received his Ph.D. in Molecular Biology from Howard University in Washington, D.C., and performed postdoctoral studies at the University of Maryland Medical Center and George Washington University Medical Center. Dr. Davenport also serves on the advisory board the New Orleans BioInnovation Center, www.neworleansbio.com and the Mount St. Mary’s University Biotechnology & Management Program, www.msmary.edu.

 
 
edited.jpg
 
 

Jenna Matheny

Jenna joined the Belfer Office for Dana-Farber Innovations in 2017 and is currently the Innovation and Licensing Lead for immunology and virology; software, data sciences, and computational biology; prevention and early detection; population sciences; molecular biology; and cellular therapies at Dana-Farber. Previously, she was a Licensing Associate at Tulane University in New Orleans, Louisiana, where she managed the protection and commercialization of intellectual property developed across the university – ranging from life sciences to clean energy. Prior to joining Tulane, Jenna worked with the New Orleans BioInnovation Center to support the development of startups based on technologies licensed from New Orleans-area universities.

Jenna received her JD degree from Tulane University Law School and her SB in Brain and Cognitive Sciences from MIT. She is a member of the Board of Directors of LouisianaBio and is active with the Association of University Technology Managers.